Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 43

  • Showing results for david viola. Your search for davidviola retrieved no results.
1.

Medullary thyroid cancer treated with vandetanib: predictors of longer and durable response.

Valerio L, Bottici V, Matrone A, Piaggi P, Viola D, Cappagli V, Agate L, Molinaro E, Ciampi R, Tacito A, Ramone T, Romei C, Elisei R.

Endocr Relat Cancer. 2019 Dec 1. pii: ERC-19-0259.R2. doi: 10.1530/ERC-19-0259. [Epub ahead of print]

PMID:
31804969
2.

BRAF V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma.

Kim KJ, Kim SG, Tan J, Shen X, Viola D, Elisei R, Puxeddu E, Fugazzola L, Colombo C, Jarzab B, Czarniecka A, Lam AK, Mian C, Vianello F, Yip L, Riesco-Eizaguirre G, Santisteban P, O'Neill CJ, Sywak MS, Clifton-Bligh R, Bendlova B, Sýkorová V, Xing M.

Eur J Cancer. 2019 Nov 29;124:161-169. doi: 10.1016/j.ejca.2019.10.017. [Epub ahead of print]

PMID:
31790974
3.

Active surveillance in papillary thyroid microcarcinomas is feasible and safe: experience at one single Italian center.

Molinaro E, Campopiano MC, Pieruzzi L, Matrone A, Agate L, Bottici V, Viola D, Cappagli V, Valerio L, Giani C, Puleo L, Lorusso L, Piaggi P, Torregrossa L, Basolo F, Vitti P, Tuttle RM, Elisei R.

J Clin Endocrinol Metab. 2019 Oct 25. pii: dgz113. doi: 10.1210/clinem/dgz113. [Epub ahead of print]

PMID:
31652318
4.

Lenvatinib Administered via Nasogastric Tube in Poorly Differentiated Thyroid Cancer.

Molinaro E, Viola D, Viola N, Falcetta P, Orsolini F, Torregrossa L, Vagli P, Ribechini A, Materazzi G, Vitti P, Elisei R.

Case Rep Endocrinol. 2019 Sep 18;2019:6831237. doi: 10.1155/2019/6831237. eCollection 2019.

5.

Genetic Landscape of Somatic Mutations in a Large Cohort of Sporadic Medullary Thyroid Carcinomas Studied by Next-Generation Targeted Sequencing.

Ciampi R, Romei C, Ramone T, Prete A, Tacito A, Cappagli V, Bottici V, Viola D, Torregrossa L, Ugolini C, Basolo F, Elisei R.

iScience. 2019 Oct 25;20:324-336. doi: 10.1016/j.isci.2019.09.030. Epub 2019 Sep 26.

6.

DELAYED 131-I FIRST TREATMENT AFTER SURGERY HAS NO IMPACT ON THE MEDIAN TERM OUTCOME OF PATIENTS WITH INTERMEDIATE RISK DIFFERENTIATED THYROID CANCER.

Matrone A, Gambale C, Torregrossa L, Piaggi P, Bianchi F, Valerio L, Viola D, Agate L, Molinaro E, Materazzi G, Basolo F, Vitti P, Elisei R.

Endocr Pract. 2019 Sep 26. doi: 10.4158/EP-2019-0182. [Epub ahead of print]

PMID:
31557080
7.

Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations.

Elisei R, Tacito A, Ramone T, Ciampi R, Bottici V, Cappagli V, Viola D, Matrone A, Lorusso L, Valerio L, Giani C, Campopiano C, Prete A, Agate L, Molinaro E, Romei C.

Genes (Basel). 2019 Sep 10;10(9). pii: E698. doi: 10.3390/genes10090698.

8.

Less than 2% of the Low- and Intermediate-Risk Differentiated Thyroid Cancers Show Distant Metastases at Post-Ablation Whole-Body Scan.

Agate L, Bianchi F, Brozzi F, Santini P, Molinaro E, Bottici V, Viola D, Lorusso L, Vitti P, Elisei R.

Eur Thyroid J. 2019 Apr;8(2):90-95. doi: 10.1159/000494290. Epub 2018 Dec 13.

9.

Risk of incident circulatory disease in patients treated for differentiated thyroid carcinoma with no history of cardiovascular disease.

Toulis KA, Viola D, Gkoutos G, Keerthy D, Boelaert K, Nirantharakumar K.

Clin Endocrinol (Oxf). 2019 Aug;91(2):323-330. doi: 10.1111/cen.13990. Epub 2019 May 17.

PMID:
30993728
10.

Management of Medullary Thyroid Cancer.

Viola D, Elisei R.

Endocrinol Metab Clin North Am. 2019 Mar;48(1):285-301. doi: 10.1016/j.ecl.2018.11.006. Epub 2018 Dec 26. Review.

PMID:
30717909
11.

Fifty Years After the First Description, MEN 2B Syndrome Diagnosis Is Still Late: Descriptions of Two Recent Cases.

Elisei R, Matrone A, Valerio L, Molinaro E, Agate L, Bottici V, Viola D, Giani C, Cappagli V, Latrofa F, Materazzi G, Torregrossa L, Ugolini C, Basolo F, Romei C.

J Clin Endocrinol Metab. 2019 Jul 1;104(7):2520-2526. doi: 10.1210/jc.2018-02102.

PMID:
30597074
12.

Lung Recurrence of Papillary Thyroid Cancer Diagnosed With Antithyroglobulin Antibodies After 10 Years From Initial Treatment.

Viola D, Agate L, Molinaro E, Bottici V, Lorusso L, Latrofa F, Torregrossa L, Boldrini L, Ramone T, Vitti P, Elisei R.

Front Endocrinol (Lausanne). 2018 Oct 9;9:590. doi: 10.3389/fendo.2018.00590. eCollection 2018.

13.

BRAF V600E Confers Male Sex Disease-Specific Mortality Risk in Patients With Papillary Thyroid Cancer.

Wang F, Zhao S, Shen X, Zhu G, Liu R, Viola D, Elisei R, Puxeddu E, Fugazzola L, Colombo C, Jarzab B, Czarniecka A, Lam AK, Mian C, Vianello F, Yip L, Riesco-Eizaguirre G, Santisteban P, O'Neill CJ, Sywak MS, Clifton-Bligh R, Bendlova B, Sýkorová V, Wang Y, Xing M.

J Clin Oncol. 2018 Sep 20;36(27):2787-2795. doi: 10.1200/JCO.2018.78.5097. Epub 2018 Aug 2.

14.

Clinical, pathological and genetic features of anaplastic and poorly differentiated thyroid cancer: A single institute experience.

Romei C, Tacito A, Molinaro E, Piaggi P, Cappagli V, Pieruzzi L, Matrone A, Viola D, Agate L, Torregrossa L, Ugolini C, Basolo F, De Napoli L, Curcio M, Ciampi R, Materazzi G, Vitti P, Elisei R.

Oncol Lett. 2018 Jun;15(6):9174-9182. doi: 10.3892/ol.2018.8470. Epub 2018 Apr 12.

15.

Patient Age-Associated Mortality Risk Is Differentiated by BRAF V600E Status in Papillary Thyroid Cancer.

Shen X, Zhu G, Liu R, Viola D, Elisei R, Puxeddu E, Fugazzola L, Colombo C, Jarzab B, Czarniecka A, Lam AK, Mian C, Vianello F, Yip L, Riesco-Eizaguirre G, Santisteban P, O'Neill CJ, Sywak MS, Clifton-Bligh R, Bendlova B, Sýkorová V, Xing M.

J Clin Oncol. 2018 Feb 10;36(5):438-445. doi: 10.1200/JCO.2017.74.5497. Epub 2017 Dec 14.

16.

BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment.

Huang Y, Qu S, Zhu G, Wang F, Liu R, Shen X, Viola D, Elisei R, Puxeddu E, Fugazzola L, Colombo C, Jarzab B, Czarniecka A, Lam AK, Mian C, Vianello F, Yip L, Riesco-Eizaguirre G, Santisteban P, O'Neill CJ, Sywak MS, Clifton-Bligh R, Bendlova B, Sýkorová V, Xing M.

J Natl Cancer Inst. 2018 Apr 1;110(4):362-370. doi: 10.1093/jnci/djx227.

17.

Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life.

Matrone A, Valerio L, Pieruzzi L, Giani C, Cappagli V, Lorusso L, Agate L, Puleo L, Viola D, Bottici V, Del Re M, Molinaro E, Danesi R, Elisei R.

Best Pract Res Clin Endocrinol Metab. 2017 Jun;31(3):319-334. doi: 10.1016/j.beem.2017.06.001. Epub 2017 Jun 15. Review.

PMID:
28911728
18.

KIF5B/RET Rearrangement in a Carcinoma of the Thyroid Gland: A Case Report of a Fatal Disease.

Viola D, Giani C, Mazzeo S, Ugolini C, Ciampi R, Molinaro E, Agate L, Borrelli N, Chella A, Fontanini G, Basolo F, Elisei R.

J Clin Endocrinol Metab. 2017 Sep 1;102(9):3091-3096. doi: 10.1210/jc.2017-00304.

PMID:
28911147
19.

The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer.

Wang F, Yu X, Shen X, Zhu G, Huang Y, Liu R, Viola D, Elisei R, Puxeddu E, Fugazzola L, Colombo C, Jarzab B, Czarniecka A, Lam AK, Mian C, Vianello F, Yip L, Riesco-Eizaguirre G, Santisteban P, O'Neill CJ, Sywak MS, Clifton-Bligh R, Bendlova B, Sýkorová V, Wang Y, Liu S, Zhao J, Zhao S, Xing M.

J Clin Endocrinol Metab. 2017 Sep 1;102(9):3241-3250. doi: 10.1210/jc.2017-00277.

20.

Postoperative Thyroglobulin and Neck Ultrasound in the Risk Restratification and Decision to Perform 131I Ablation.

Matrone A, Gambale C, Piaggi P, Viola D, Giani C, Agate L, Bottici V, Bianchi F, Materazzi G, Vitti P, Molinaro E, Elisei R.

J Clin Endocrinol Metab. 2017 Mar 1;102(3):893-902. doi: 10.1210/jc.2016-2860.

PMID:
27929713

Supplemental Content

Loading ...
Support Center